Live Breaking News & Updates on Peter Borchmann

Stay updated with breaking news from Peter borchmann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma

OSAKA, Japan & CAMBRIDGE, Mass. & NEW YORK (BUSINESS WIRE) Jun 1, 2024 ....

United States , John Cunningham , Jun Saito , Peter Borchmann , Exchange Commission , American Society Of Clinical Oncology , International Media , University Hospital Of Cologne , Important Safety Information European Union , International Agency For Research On Cancer , Health Canada , European Union , Takeda Pharmaceutical Company , German Hodgkin Study Group , Takeda Pharmaceutical Company Limited , European Hematology Association , American Society , Clinical Oncology , Annual Meeting , University Hospital , International Agency , European Commission , Important Safety Information , Product Characteristics , Hepatic Impairment , Prescribing Information ,

Adcetris Regimen Outperforms Intense Chemo in Classical Hodgkin Lymphoma

An Adcetris-based treatment regimen improved progression-free survival and was more tolerable for patients with classical Hodgkin lymphoma. ....

United States , Peter Borchmann , University Hospital Cologne , American Society Of Clinical Oncology Annual Meeting , Clinical Oncology Annual , Integrated Oncology ,

BrECADD Regimen Improves PFS vs eBEACOPP Regimen in Advanced Classical Hodgkin Lymphoma

Four-year progression-free survival outcomes revealed the BrECADD regimen was superior to the eBEACOPP regimen, and BrECADD had a promising benefit-risk profile. ....

Peter Borchmann , Department Of Haematology , Certified Centre For Haematological Malignancies , German Hodgkin Study Group , University Hospital Of Cologne , Certified Centre , Haematological Malignancies , University Hospital ,

Kinder, Gentler Regimen for Classical Hodgkin Prevails in Randomized Trial

Better efficacy with brentuximab vedotin versus standard chemo, substantially less toxicity ....

United States , Dana Farber Cancer Institute , Peter Borchmann , Charles Bankhead , Julie Gralow , Oreofeo Odejide , University Hospital Of Cologne , German Hodgkin Study Group , American Society Of Clinical Oncology , University Hospital , American Society , Clinical Oncology , Medpage Today ,

BrECADD Proves Noninferior to eBEACOPP in Advanced Classical Hodgkin Lymphoma

The BrECADD combination had noninferior efficacy and superior tolerability compared with escalated BEACOPP in patients with advanced classical Hodgkin lymphoma, according to data from the phase 3 HD21 trial. ....

Peter Borchmann , Moccia Al , Lymphoma Program , Department Of Hematology , German Hodgkin Study Group , University Hospital Of Cologne , Bristol Myers Squibb , International Conference On Malignant Lymphoma , Seagen Inc , International Conference , Malignant Lymphoma , University Hospital , Takeda Oncology , Miltenyi Biotech ,